Disclaimer: AI generated image
Over the last several weeks, I have had a series of conversations with emerging biotech leaders that all landed in roughly the same place. Different companies. Different modalities. Different stages. Same underlying challenge.
How do you prove good science in an environment that allows very little room for error, very little tolerance for delay, and very little forgiveness for missteps that cost time and capital?
This is not a new question. But the way it is showing up lately feels different. More urgent. Less theoretical. And, at times, more frustrating than it should be.
What struck me was not the emotion behind these conversations, which is understandable. It was the consistency.
When independent leaders, having separate experiences, keep describing the same obstacles in almost identical language, it is usually a signal worth paying attention to.
The Reality of Early-Stage Biotech Today
For emerging biotech, innovation is no longer judged solely by the quality of the science. It is judged by the ability to move that science forward, cleanly and quickly, under intense pressure.
Capital is tighter. Milestones matter more. Investor patience is thinner. Timelines that slip by months can set companies back by years. In some cases, they end companies altogether.
In this environment, every partner becomes strategic by default. Especially the ones responsible for early development and execution. CROs are not vendors in this phase. They are extensions of the company. When they perform well, nobody notices. When they do not, everyone does.
This is where a noticeable tension keeps showing up in conversation.
Leaders are describing experiences where programs miss timelines, experiments must be repeated, data quality becomes a discussion instead of a given, and accountability turns into a negotiation. When things go wrong, the response is often credits toward future work, which sounds generous until you realize the future work still depends on the same system that created the problem in the first place.
Time is lost. Money is burned. Trust is strained. Nobody feels particularly innovative at the end of it.
To be clear, this is not universal. There are excellent CROs and exceptional teams doing difficult work well. But enough people are sharing similar frustrations that it feels less like isolated bad experiences and more like a structural issue.
Where the Conversation Gets Interesting
In these discussions, one organization kept coming up. Not because anyone was trying to promote them. WuXi Biologics.
What people described was not a brand preference. It was an experience difference.
Video meetings with ten or twelve people, all relevant, all prepared. Questions that demonstrated listening rather than selling. Solutions offered quickly and adjusted just as quickly when something did not quite fit. Execution that moved faster than expected, with fewer surprises along the way.
Several leaders mentioned that they had tried U.S. based CROs first. The hope was familiarity, proximity, and alignment. The outcome, in more than one case, was disappointment. Missed timelines. Experiments that had to be repeated. Time spent negotiating refunds or credits instead of advancing the science.
The contrast was not framed as ideological or political. It was practical.
Which partner got the work done, correctly, on time, without turning every issue into a prolonged discussion?
That is a hard question to ignore.
This Is Not About East Versus West
It would be easy to turn this into a geopolitical story, or a morality play about outsourcing. That would also be lazy and unhelpful. The more interesting question is structural.
What are we optimizing for in biotech execution today?
Many traditional CRO models are still built around utilization, billing, and customized workflows. These incentives make sense in stable environments. They make far less sense when early-stage biotech companies need speed, clarity, and accountability more than they need bespoke processes. WuXi appears to have optimized for something different.
“Platformized” science instead of constant reinvention. Deep benches instead of lean staffing models stretched thin. Integrated teams instead of handoffs between groups that assume someone else owns the outcome. Speed is not treated as a nice to have. It is treated as part of the value proposition.
This is not about being cheaper alone. It is about being predictable. It is about reducing friction. It is about earning trust by delivering exactly what was promised, when it was promised.
In a capital constrained environment, that combination matters more than most people want to admit.
The Cost of Getting This Wrong
For large, well-capitalized organizations, inefficiencies are frustrating. For emerging biotech companies, they will kill it.
Every delay compounds risk. Every rework cycle forces difficult decisions about what to pause, what to fund, and what to abandon. Every missed commitment makes the next fundraising conversation harder.
When execution fails, it is rarely just a technical issue. It becomes a credibility issue.
Innovation does not die because ideas are bad. It dies because systems are misaligned.
What Does Catching Up Actually Mean?
If the goal is to accelerate innovation and keep emerging biotech competitive, then copying any one company is probably not the answer. Understanding what they have built is.
This likely requires uncomfortable changes.
Incentives that reward outcomes rather than hours. Earlier engagement of real scientific depth instead of thinly staffed teams. Greater standardization where it reduces risk, even if it challenges long held preferences for customization. Willingness to treat early-stage clients as fragile ecosystems rather than long term revenue streams.
It also requires listening. Not marketing listening, but real listening. The kind where leaders hear what founders are experiencing and resist the urge to explain why the system works as designed. Because the system may be working exactly as designed. That might be the problem.
A Final Thought
Innovation in biotech is often depicted as a breakthrough moment. A discovery. A platform. A leap forward.
It is more often slowed or accelerated by execution. By decisions that happen quietly, far from headlines, inside development plans and project meetings.
If multiple founders are telling the same story, we should not dismiss it as anecdotal noise. It is feedback. The question is not whether we like the example they are pointing to. The question is what we are willing to learn from it.
If speed, trust, and execution have become prerequisites for innovation, then we need systems that reflect that reality.
Otherwise, we will keep having the same conversations. Just with less runway each time.